Impact of free light chain hemodialysis in myeloma cast nephropathy: A case-control study

Hemodialysis International

Volumn 15, Issue 4, 2011, Pages 538-545

  Peters, Nicolas O ^a   Laurain, Emmanuelle ^a   Cridlig, Joëlle ^a   Hulin, Cyrille ^a   Cao Huu, Thanh ^a   Frimat, Luc ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Acute renal failure; Cast nephropathy; Myeloma; Very high permeability membranes

Indexed keywords

PARAPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY BIOPSY; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANE PERMEABILITY; MORTALITY; MULTIPLE MYELOMA; MYELOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY;

AGED; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 80054890885     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00587.x     Document Type: Article

References (24)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009; 374:324-339.
2. Islam A, Ambrus JL. Bortezomib plus melphalan and prednisone for multiple myeloma. N Engl J Med. 2008; 359:2613.
3. Durie BG. Treatment of myeloma-Are we making progress? N Engl J Med. 2008; 359:964-966.
4. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Eur J Haematol. 2000; 65:175-181.
5. Pillon L, Sweeting RS, Arora A, etal. Approach to acute renal failure in biopsy proven myeloma cast nephropathy: Is there still a role for plasmapheresis? Kidney Int. 2008; 74:956-961.
6. Basnayake K, Hutchinson CA, Kamel D, etal. Resolution of cast nephropathy following free light chain removal by hemodialysis in a patient with multiple myeloma: A case report. J Med Case Rep. 2008; 2:380.
7. Hutchison CA, Cockwell P, Stringer S, etal. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011; 22:1129-1136.
8. Tsakiris DJ, Stel VS, Finne P, etal. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: An ERA-EDTA Registry study. Nephrol Dial Transplant. 2010; 25:1200-1206.
9. Torra R, Blade J, Cases A, etal. Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol. 1995; 91:854-859.
10. Ahmad M. Continuous ambulatory peritoneal dialysis in patients with renal failure due to multiple myeloma. Int Urol Nephrol. 2007; 39:629-633.
11. Korzets A, Tam F, Russell G, Feehally J, Walls J. The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis. 1990; 16:216-223.
12. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988; 33:1175-1180.
13. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990; 150:863-869.
14. Clark WF, Stewart AK, Rock GA, etal. Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med. 2005; 143:777-784.
15. Clark WF, Garg AX. Plasma exchange for myeloma kidney: Cast(s) away? Kidney Int. 2008; 73:1211-1213.
16. Leung N, Gertz MA, Zeldenrust SR, etal. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008; 73:1282-1288.
17. Hutchison CA, Cockwell P, Reid S, etal. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In vitro and in vivo studies. J Am Soc Nephrol. 2007; 18:886-895.
18. Hutchison CA, Bradwell AR, Cook M, etal. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009; 4:745-754.
19. Kleeberg L, Morgera S, Jakob C, etal. Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy. Eur J Med Res. 2009; 14:47-54.
20. Bachmann U, Schindler R, Storr M, Kahl A, Joernes A, Sturm I. Combination of bortezomib based chemotherapy and extracorpeal free light chain removal for treating cast nephropathy in myeloma multiple. NDT Plus. 2008; 1:106-108.
21. Couchoud C, Lassalle M, Stengel B, Jacquelinet C. Renal Epidemiology and Information Network: 2007 annual report. Nephrol Ther. 2009; 5:S3-144.
22. Hutchison CA, Cook M, Heyne N, etal. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials. 2008; 9:55.
23. Hutchison CA, Harding S, Hewins P, etal. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3:1684-1690.
24. Hutchison CA, Plant T, Drayson M, etal. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008; 9:11.